NRX Pharmaceuticals (NRXP) Stock: Buy, Sell, or Hold?
NRXP - NRX Pharmaceuticals, Inc. Common Stock
$2.49
0.09 (3.75%)
▲
5d:
-4.23%
30d:
-17.82%
90d:
-31.4%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 13, 2026
20d
Get Alerted When NRXP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NRXP shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NRXP shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NRXP is currently trading at $2.49, which is considered oversold relative to its 30-day fair value range of $2.62 to $3.22. From a valuation perspective, the stock is trading at a discount (Forward PE: -7.1) compared to its historical average (9.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NRXP is in a strong downtrend. Immediate support is located at $2.24, while resistance sits at $2.93. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: NRXP scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.50 (+1446.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NRXP is in a strong downtrend. Immediate support is located at $2.24, while resistance sits at $2.93. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: NRXP scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $38.50 (+1446.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.62 -
$3.22
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
Protect Your Profits
Holding NRXP? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 1446.2% below Wall St target ($38.50)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.62 -
$3.22
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.24
Resistance Level
$2.93
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.11
Wall Street Target
$38.50
(+1446.2%)
PE vs Historical
-7.1 vs 9.4
CHEAP
Share & Embed Analysis
Last updated: October 23, 2026 5:12 PM ET
Data refreshes hourly during market hours. Next update: 6:12 PM
Data refreshes hourly during market hours. Next update: 6:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NRXP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
|
CGON
CG Oncology, Inc. Common… |
STRONG BUY
15 analysts |
$91 | 64 BUY |
Advanced NRXP Option Strategies
Professional options setups generated by AI based on today's NRXP price and gamma walls.
